Please use this identifier to cite or link to this item:
|Title:||Antibody therapy of cancer.|
|Authors:||Scott, Andrew M;Wolchok, Jedd D;Old, Lloyd J|
|Affiliation:||Ludwig Institute for Cancer Research; University of Melbourne; and Centre for PET, Austin Hospital, Melbourne, Victoria 3084, Australia. firstname.lastname@example.org|
|Citation:||Nature Reviews. Cancer 2012; 12(4): 278-87|
|Abstract:||The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.|
|Internal ID Number:||22437872|
Antibodies, Monoclonal.pharmacokinetics.pharmacology.therapeutic use
Antineoplastic Agents.pharmacokinetics.pharmacology.therapeutic use
Clinical Trials as Topic
Drug Carriers.therapeutic use
Drug Resistance, Neoplasm
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.